medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2014, Number 3

<< Back Next >>

Biotecnol Apl 2014; 31 (3)

Implementation of a competitive ELISA for pharmacokinetics studies of CIGB-300 in human plasma

Reyes V, Perera Y, Díaz E, Rosales I, García G, Perea SE

Language: English
References: 26
Page: 232-236
PDF size: 260.52 Kb.


ABSTRACT

CIGB-300 is a synthetic peptide that inhibits the phosphorylation mediated by enzyme casein kinase 2 (CK2) and has a marked antineoplastic effect in different preclinical models. In the clinical setting, it’s explored in phase I and II studies using different routes of administration. In particular, the use of the intravenous route requires a reliable analytical method for the detection of CIGB-300 in plasma. A competitive ELISA was developed to detect and quantify the CIGB-300 peptide in human plasma samples. This system showed a detection limit of 0.030 µg/mL and a working range from 10 to 0.039 µg/mL, including concentrations achieved in plasma of patients treated with CIGB-300. In addition, the intra and inter-assay precisions were (coefficient of variation ‹ 5 %) and (CV ‹ 17 %) and the recovered range from 98.9 to 119.8 %. Finally, the impact of three freeze-thaw cycles and the sample storage at - 80 °C on the stability of the analyte was evaluated. We obtained a CV ‹ 20 % for all samples in the stability study. The results support the application of this analytical method as a new tool for the pharmacokinetic studies of the early stages of clinical research with the new anti cancer drug CIGB-300.


REFERENCES

  1. Perea SE, Reyes O, Puchades Y, Mendoza O, Vispo NS, Torrens I, et al. Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer Res. 2004;64(19):7127-9.

  2. Perera Y, Costales HC, Diaz Y, Reyes O, Farina HG, Mendez L, et al. Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization. J Pept Sci. 2012;18(4):215-23.

  3. Perera Y, Farina HG, Hernandez I, Mendoza O, Serrano JM, Reyes O, et al. Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. Int J Cancer. 2008;122(1):57-62.

  4. Solares AM, Santana A, Baladron I, Valenzuela C, Gonzalez CA, Diaz A, et al. Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer. 2009;9:146.

  5. European Medicines Agency. Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins Committee for medicinal products for human use (CHMP). London: EMEA; 2007 [cited 2013 Nov 17]. Available from: http://www.ema.europa.eu/docs/ en_GB/document_library/Scientific_guideline/ 2009/09/WC500003029.pdf.

  6. Soriano-García JL, López-Díaz A, Solares- Asteasuainzarra M, Baladrón-Castrillo I, Batista-Albuerne N, García-García I, et al. Pharmacological and safety evaluation of CIGB-300, a casein kinase 2 inhibitor peptide, administered intralesionally to patients with cervical cancer stage IB2/ II. J Cancer Res Ther. 2013;1(6):163-73.

  7. Richter M, Cyranka U, Nowak G, Walsmann P. Pharmacokinetics of 125I-hirudin in rats and dogs. Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115(1- 2):64-9.

  8. Lequin RM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem. 2005;51(12):2415-8.

  9. Wild D, editor. The immunoassay Hand-book. 2nd ed. London: Nature Publishing Group; 2001.

  10. Bansal S, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J. 2007;9(1):E109-14.

  11. Seeber S, Issinger OG, Holm T, Kristensen LP, Guerra B. Validation of protein kinase CK2 as oncological target. Apoptosis. 2005;10(4):875-85.

  12. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 1960;39:1157-75.

  13. Ekins RP. The estimation of thyroxine in human plasma by an electrophoretic technique. Clin Chim Acta. 1960;5:453-9.

  14. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry. 1971;8(9):871-4.

  15. Van Weemen BK, Schuurs AH. Immunoassay using antigen-enzyme conjugates. FEBS Lett. 1971;15(3):232-6.

  16. Zakowicz, H. A 40-Year-Old Paradox: The Fascinating History of the ELISA. Boster Inmunoleader; 2013.

  17. DeSilva B, Smith W, Weiner R, Kelley M, Smolec J, Lee B, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res. 2003;20(11):1885-900.

  18. U.S. Department of Health and Human Services. Guidance for Industry: Bioanalytical Method Validation. Rockville: US Department of Health and Human Services; 2001 [cited 2013 Nov 17]. Available from: http://www.fda.gov/downloads/Drugs/ Guidances/ucm070107.pdf

  19. Kelley M, DeSilva B. Key elements of bioanalytical method validation for macromolecules. The AAPS J. 2007;9(2):E156-63.

  20. Findlay JW, Dillard RF. Appropriate calibration curve fitting in ligand binding assays. The AAPS journal. 2007;9(2):E260-7.

  21. Ministry of Health, Labour and Welfare of Japan. Draft Guideline on Bioanalytical Method (Ligand Binding Assay) Validation in Pharmaceutical Development. Tokyo: MHLW; 2014 [cited 2014 Jan 27]. Available from: http://www.nihs.go.jp/drug/BMV/ BMV-LBA_draft_140124_E_rev.pdf

  22. Matsui T, Imamura M, Oka H, Osajima K, Kimoto K, Kawasaki T, et al. Tissue distribution of antihypertensive dipeptide, Val-Tyr, after its single oral administration to spontaneously hypertensive rats. J Pept Sci. 2004;10(9):535-45.

  23. Lax R, Meenan, Ch. Challenges for Therapeutic Peptides Part 1: On the Inside, Looking Out. Innovations in Pharmaceutical Technology. 2012(42):54-6.

  24. Fineman M, Flanagan S, Taylor K, Aisporna M, Shen LZ, Mace KF, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2011;50(1):65-74.

  25. Creative Diagnostics. Heloderma Suspectum Exendin-4 ELISA Kit Cat. No. DEIA10583. New York: Creative Diagnostics; 2013 [cited 2013 Nov 17]. Available from: http://img2.creative-diagnostics. com/pdf/DEIA10583,Exendin-4.pdf

  26. Koliaraki V, Marinou M, Vassilakopoulos TP, Vavourakis E, Tsochatzis E, Pangalis GA, et al. A novel immunological assay for hepcidin quantification in human serum. PLoS One. 2009;4(2):e4581.




2020     |     www.medigraphic.com